Funder: Food and Drug Administration (FDA)
Due Dates: Archived as of May 26, 2021 (no current deadlines)
Funding Amounts: Not specified; cooperative agreement funding mechanism
Summary: Supports innovative clinical trial designs and strategic collaborations to advance development of analgesic, anesthetic, addiction, and peripheral neuropathy medications.
Key Information: Multi-year, multi-phase public-private partnership aligned with FDA's Critical Path Initiative; no current open application period.
The Analgesic, Anesthetic and Addiction Clinical Trials Innovations, Opportunities, and Networks (ACTTION) is a multi-year, multi-phase public-private partnership (PPP) led by the Food and Drug Administration (FDA). It is aligned with the FDA's Critical Path Initiative to accelerate and streamline the discovery and development of new medications targeting pain (analgesics), anesthesia, addiction, and peripheral neuropathy.
ACTTION aims to develop innovative clinical trial designs that enhance regulatory decision-making processes. The initiative fosters strategic collaborations among a broad spectrum of stakeholders, including academic researchers, government agencies (FDA and others), industry partners, professional organizations, and patient advocacy groups. These collaborations focus on sharing data and innovative ideas to improve the development of novel therapeutics.
Activities supported under ACTTION include a wide range of research projects, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data. A key focus is on understanding how research methods affect study assay sensitivity and efficiency, ultimately improving the quality and impact of clinical trials in these therapeutic areas.
Eligible applicants include a wide range of organizations:
ACTTION is designed to support the FDA’s mission to protect public health by improving the development and evaluation of drugs in the areas of pain, anesthesia, addiction, and neuropathy. The initiative encourages innovative approaches to clinical trial design and regulatory science, aiming to enhance the efficiency and sensitivity of studies that inform regulatory decisions.
| Contact Person | Shashi Malhotra, Grants Management Specialist |
|---|---|
| shashi.malhotra@fda.hhs.gov | |
| Phone | (888) 463-6332 |
| Funder Organization | Food and Drug Administration (FDA) |
| Funder Address | 10903 New Hampshire Ave, Silver Spring, MD 20993-0002 |